Metyrapone
From Wikipedia, the free encyclopedia
 |
|
|
Metyrapone
|
|
| Systematic (IUPAC) name | |
| 2-methyl-1,2-dipyridin-3-yl-propan-1-one | |
| Identifiers | |
| CAS number | |
| ATC code | V04 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C14H14N2O |
| Mol. mass | 226.274 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 1.9 ±0.7 hours. |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
C US |
| Legal status | |
| Routes | Oral |
Metyrapone (Metopirone™) is a drug used in the diagnosis of adrenal insufficiency, and occasionally the treatment, of Cushing's syndrome (hypercortisolism). Metyrapone blocks cortisol synthesis by inhibiting 11B hydroxylase. this stimulates ACTH secretion, which in turn increases plasma 11- deoxycortisol levels. When excess ACTH secretion is the cause of hypercortisolism, the metyrapone test helps clarify if the source of the ACTH is pituitary or ectopic (non-pituitary).
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
